Please login to the form below

Not currently logged in
Email:
Password:

tofacitinib citrate

This page shows the latest tofacitinib citrate news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Cosentyx misses the mark in Humira head-to-head

Novartis’ Cosentyx misses the mark in Humira head-to-head

This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).

Latest news

  • Novartis eyes potential new indication for Cosentyx Novartis eyes potential new indication for Cosentyx

    This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).

  • J&J's Tremfya filed for approval in US for psoriatic arthritis J&J's Tremfya filed for approval in US for psoriatic arthritis

    This includes Novartis’ Consentyx (secukinumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate) , which are all already approved in psoriatic arthritis.

  • NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’s Xeljanz for RA

    But UK’s cost-effectiveness watchdog removes two drugs from CDF. Pfizer is celebrating a positive recommendation from the National Institute for Health and Care Excellence (NICE) for Xeljanz (tofacitinib citrate), ... alone. Mason added: “We are

  • Pfizer closes on Xeljanz filing in ulcerative colitis Pfizer closes on Xeljanz filing in ulcerative colitis

    Xeljanz (tofacitinib) is already approved to treat rheumatoid arthritis (RA) but has failed to grow as quickly as hoped in that setting, so the US pharma giant is hoping new indications ... In addition to UC, the FDA approved Xeljanz XR (tofacitinib

  • Pfizer to work with genetics firm on bowel disease Pfizer to work with genetics firm on bowel disease

    Pfizer has existing interests and expertise in the area, including the autoimmune therapy Xeljanz (tofacitinib citrate), which is currently approved for rheumatoid arthritis in certain regions and is being investigated in

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics